HEY1 and neoplasm: Another study also indicated that MK-0752 treatment with or without docetaxel in mice bearing human tumorgrafts reduced the primary and secondary mammosphere-forming efficiency (MSFE); decreased the ALDH+ and CD44+/CD24− subpopulations; downregulated NICD, Hes1, Hey1, Hes5, and Myc; and reduced tumor growth.